CIK 0001549595
- Large accelerated filer
Nurix Therapeutics, Inc.
Sign in to watch- Ticker
- NRIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Nov 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 270838048
- Phone
- +1 415-660-5320
- Business address
- 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
- Former names
- Nurix, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,712,859
- in 10 filings, $1.0M under 10b5-1 plans
Net −$1,712,859. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 1 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-06-01 | Hansen Gwenn Chief Scientific Officer | Exercise or conversion · Employee Stock Option (right to buy) | −400 | 72,266 | ||
| 2021-05-28 | SIEGALL CLAY B Director | Grant or award · Director Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2021-05-10 | Ring Christine General Counsel | Exercise or conversion | +1,200 | $1.86 | $2K | 2,005 |
| 2021-05-10 | Ring Christine General Counsel | Sale | −1,200 | $27.00 | $32K | 805 |
| 2021-05-10 | Ring Christine General Counsel | Exercise or conversion · Employee Stock Option (right to buy) | −1,200 | 114,466 | ||
| 2021-05-10 | Beaurang Pierre Chief Business Officer | Exercise or conversion | +7,500 | $1.11 | $8K | 11,830 |
| 2021-05-10 | Beaurang Pierre Chief Business Officer | Sale | −4,299 | $26.07 | $112K | 7,531 |
| 2021-05-10 | Beaurang Pierre Chief Business Officer | Sale | −2,501 | $26.87 | $67K | 5,030 |
| 2021-05-10 | Beaurang Pierre Chief Business Officer | Sale | −700 | $27.66 | $19K | 4,330 |
| 2021-05-10 | Beaurang Pierre Chief Business Officer | Exercise or conversion · Employee Stock Option (right to buy) | −7,500 | 29,062 | ||
| 2021-05-06 | Tong Jeffrey K Director | Grant or award · Director Stock Option (right to buy) | +17,500 | 17,500 | ||
| 2021-05-06 | Lacey David L. Director | Grant or award · Director Stock Option (right to buy) | +17,500 | 17,500 | ||
| 2021-05-06 | Kunkel Lori Anne Director | Grant or award · Director Stock Option (right to buy) | +17,500 | 17,500 | ||
| 2021-05-06 | GREGORY JULIA P Director | Grant or award · Director Stock Option (right to buy) | +17,500 | 17,500 | ||
| 2021-05-06 | Chen Leon Director | Grant or award · Director Stock Option (right to buy) | +17,500 | 17,500 | ||
| 2021-05-06 | Third Rock Ventures III, L.P. 10% owner | Other disposition | −1,085,784 | 3,422,549 | ||
| 2021-05-05 | COLUMN GROUP L P 10% owner | Other disposition | −2,000,000 | 1,394,333 | ||
| 2021-05-05 | COLUMN GROUP L P 10% owner | Other acquisition | +438,338 | 438,338 | ||
| 2021-05-05 | COLUMN GROUP L P 10% owner | Other acquisition | +10,307 | 10,307 | ||
| 2021-05-05 | COLUMN GROUP L P 10% owner | Other acquisition | +10,307 | 10,307 |
Page 34 of 42 · 829 trades